Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncoimmunology. 2014 Jan 1;3(1):e27296.

Anti-HER2/Neu passive-aggressive immunotherapy.

Author information

  • 1Department of Melanoma Medical Oncology-Research; MD Anderson Cancer Center; Houston, TX USA.
  • 2Department of Pathology and Committee on Immunology; University of Chicago; Chicago, IL USA.

Abstract

Preclinical studies have established that CD8+ T cells are necessary for efficient immunotherapeutic regimens targeting v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2, best known as HER2/Neu). Recently, we extended upon these findings by demonstrating that anti-HER2/Neu therapy also requires CD4+ T cells and CD40/CD40L signaling within the tumor microenvironment. Our results add to mounting evidence demonstrating that adaptive immunity is crucial to the efficacy of conventional and targeted anticancer chemotherapeutics.

KEYWORDS:

CD4; CD40; CD40L; CD8; HER2; Herceptin; adaptive immunity; antibody; immunotherapy; neu

PMID:
24605268
[PubMed]
PMCID:
PMC3935925
Free PMC Article

Images from this publication.See all images (1)Free text

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk